# Pacific Biosciences of California

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pacific-biosciences-of-california

- Industry: Biotechnology
- Headquarters: Menlo Park, US
- Website: www.pacb.com
- Total disclosed funding: $342M
- Latest round: Series F (Jul 14, 2010)
- Investors on record: 17

## About

Pacific Biosciences of California, Inc. is a US-based company specializing in innovative genomic sequencing technologies that deliver comprehensive insights into genetic data. Their solutions cater to various scientific inquiries across multiple sectors.Pacific Biosciences of California, Inc., founded in 2000 and headquartered in Menlo Park, California, focuses on advanced genomic sequencing solutions. The company has undergone significant funding events, including a Private Placement/Follow on round in February 2021, raising USD 175.00 mn, bringing the total amount raised to USD 175.00 mn. The CEO is Ameer Hamza, and the company was founded by Stephen Turner. The company has completed 18 deals to date, with its most recent deal occurring on February 10, 2021.PacBio specializes in advanced genomic sequencing technologies that merge the completeness of long reads with the precision of short reads, providing researchers with in-depth insights into genomes, transcriptomes, and epigenomes. Their product lineup features the Revio and Vega long-read systems for high-throughput sequencing, along with the Onso short-read system designed for accurate rare variant detection. These technologies serve diverse applications in human genomics, microbial research, and biopharmaceutical development, thus addressing critical needs in genetic testing and disease surveillance. The company caters to a wide range of clients including academic institutions, clinical laboratories, and research organizations across North America, Europe, and Asia.In the most recent fiscal year 2024, PacBio generated revenue of USD 154.01 mn, while its EBITDA for the same year was USD -420.96 mn. The company derives its revenue primarily from direct sales of its genomic sequencing systems and consumables, complemented by service agreements with research institutions and labs. Customers typically purchase products such as the Revio and Vega systems along with necessary consumables, thus fostering a recurring revenue model through ongoing transactions.Looking ahead, Pacific Biosciences of California, Inc. aims to launch new products which include enhancements to their existing systems and potential new offerings in genomic technologies. They are targeting expansion into new markets across Europe and Asia by 2025, leveraging the recent funding of USD 175.00 mn to support these initiatives. The funds will also aid in enhancing product development and market reach, ensuring that the company's offerings continue to meet the evolving needs of the scientific community.

## Funding rounds

- Series F, Jul 14, 2010, $8.1M — Alloy Ventures, Kleiner Perkins
- Series F, Jun 30, 2010, $101M — Alloy Ventures, Kleiner Perkins, Mohr Davidow Ventures, Morgan Stanley Investment Management, Intel Capital, DAG Ventures, AllianceBernstein, Sutter Hill Ventures, Gen-Probe Incorporated, Maverick Capital, Deerfield Management
- Series E, Aug 12, 2009, $68M — Alloy Ventures, Kleiner Perkins, Mohr Davidow Ventures, Morgan Stanley Investment Management, T Rowe Price, Wellcome Trust, Intel Capital, DAG Ventures, Ontario Teachers' Pension Plan, AllianceBernstein, Sutter Hill Ventures, Monsanto Company, Maverick Capital, Deerfield Management
- Series E, Jul 14, 2008, $100M — Alloy Ventures, Kleiner Perkins, Mohr Davidow Ventures, Morgan Stanley Investment Management, T Rowe Price, Intel Capital, AllianceBernstein, Teachers' Private Capital, Duff Ackerman & Goodrich Private Equity, Maverick Capital
- Series D, Dec 1, 2006, $50M — Alloy Ventures, Kleiner Perkins, Mohr Davidow Ventures, Maverick Capital
- Series C, Aug 26, 2005, $3M — Alloy Ventures, Kleiner Perkins, Mohr Davidow Ventures
- Series C, Aug 23, 2005, $7.7M — Alloy Ventures, Kleiner Perkins, Mohr Davidow Ventures
- Series B, Jul 1, 2004, $4.5M — Mohr Davidow Ventures

## Investors

- Mohr Davidow Ventures (https://capitalatlas.ai/funds/mohr-davidow-ventures) — Series B, Series C, Series D, Series E, Series F
- Alloy Ventures (https://capitalatlas.ai/funds/alloy-ventures) — Series C, Series D, Series E, Series F
- Kleiner Perkins (https://capitalatlas.ai/funds/kleiner-perkins) — Series C, Series D, Series E, Series F
- Maverick Capital (https://capitalatlas.ai/funds/maverick-capital) — Series D, Series E, Series F
- Morgan Stanley Investment Management — Series E, Series F
- T Rowe Price (https://capitalatlas.ai/funds/t-rowe-price) — Series E
- Intel Capital (https://capitalatlas.ai/funds/intel-capital) — Series E, Series F
- AllianceBernstein (https://capitalatlas.ai/funds/alliancebernstein) — Series E, Series F
- Teachers' Private Capital — Series E
- Duff Ackerman & Goodrich Private Equity (https://capitalatlas.ai/funds/duff-ackerman-goodrich-private-equity) — Series E
- Wellcome Trust — Series E
- DAG Ventures (https://capitalatlas.ai/funds/dag-ventures) — Series E, Series F
- Ontario Teachers' Pension Plan — Series E
- Sutter Hill Ventures (https://capitalatlas.ai/funds/sutter-hill-ventures) — Series E, Series F
- Monsanto Company — Series E
- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Series E, Series F
- Gen-Probe Incorporated — Series F